Chief investigator - Dr Victoria Potter, Kings College Hospital, London
A phase II prospective trial of prophylactic donor lymphocyte infusions for the prevention of relapse post HSCT in patients with high risk myeloid malignancy
Amount awarded: £365,336
Award start date: 01 Sep 2016
Award duration: 4 years (48 months)

Stem cell transplantation may cure acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), but unfortunately people can suffer a relapse after transplant. In this situation, there are limited treatment options, so preventing relapse is of great importance.

White blood cells called lymphocytes that come from the stem cell transplant donor can be used after transplantation to prevent relapse. This procedure is called a donor lymphocyte infusion (DLI). Currently there is no standardisation of DLI treatment in terms of a defined patient group that would benefit from this type of treatment. Timing and escalation of DLI dose is also yet to be defined.

Because of the lack of information, researchers want to assess the value of donor lymphocytes in a trial. The main potential risk of this trial is the development of graft versus host disease (GVHD) - a condition where donor lymphocytes (graft) react not only against the leukaemia but against the patients (the host) body. This trial will allow researchers to more accurately assess the effect of lymphocytes in terms of preventing relapse but also to assess the complications in terms of GVHD.

The aims of the trial are to:

  • Assess the effect of lymphocytes in terms of preventing relapse
  • Assess the complications in terms of GvHD

You may be eligible to join this trial if:

  • You have: AML, MDS or CMML
  • You are over 18 years old